Использование нестероидных противовоспалительных препаратов при полиморбидной патологии

1. Ширинский В.С., Ширинский И.В. Коморбидные заболевания – актуальная проблема клинической медицины. Сибирский медицинский журнал. 2014;29(1):7-12 [Shirinsky VS, Shirinsky IV. Comorbid diseases as an important problem of clinical medicine. Sibirskii meditsinskii zhurnal. 2014;29(1):7-12 (In Russ.)]. doi: 10.29001/2073-8552-2014-29-1-7-12
2. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н., Ивашкин В.Т., Чичасова Н.В., Алексеева Л.И. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, Ivashkin VT, Chichasova NV, Alekseeva LI, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya revmatologiya. 2015;(1):4-23 (In Russ.)]. doi: 10.14412/1996-7012-2015-1-4-23 
3. Theodoridou A, Gika H, Diza E, Garyfallos A, Settas L. In vivo study of pro-inflammatory cytokine changes in serum and synovial fluid during treatment with celecoxib and etoricoxib and correlation with VAS pain change and synovial membrane penetration index in patients with inflammatory arthritis. Mediterranian J Rheumatol. 2017;28(1):43-50. doi: 10.31138/mjr.28.1.43
4. Metzner J, Popp L, Marian C, Schmidt R, Manderscheid C, Renne C, et al.  The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice. J Molecular Medicine (Berlin). 2007;85(6):623-33. doi: 10.1007/s00109-007-0162-9
5. Schmidt M, Lamberts M, Olsen A-MS, Fosbøll E, Niessner A, Tamargo J, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016;37(13):1015-23. doi:10.1093/eurheartj/ehv505
6. Varga Z, Sabzwari S, Vargova V. Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue Cureus. 2017 Apr; 9(4):e1144. Published online 2017 Apr 8. doi: 10.7759/cureus.1144 PMCID: PMC5422108
7. Морозова Т.Е., Шмарова Д.Г., Рыкова С.М. Выбор нестероидных противовоспалительных препаратов у больных ревматологического профиля с сопутствующими сердечно-сосудистыми заболеваниями. Лечащий врач. 2016;(7):39-45 [Morozova TE, Shmarova DG, Rykova SM. The choice of non-steroidal anti-inflammatory drugs in patients with rheumatologic profile with concomitant cardiovascular diseases. Lechashii vrach. 2016;(7):39-45 (In Russ.)]. 
8. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769-79. doi:10.1016/S0140-6736(13)60900-9
9. Зотова Л.А., Петров В.С. Нестероидные противовоспалительные препараты в современной клинической практике: фокус на безопасность. Наука молодых. 2015;(1):25-30 [Zotova LA, Petrov VS. Nonsteroidal anti-inflammatory drugs in modern clinical practice: focus on safety. Nauka molodych. 2015;(1):25-30 (In Russ.)]. 
10. Насонов Е.Л. Применение нестероидных противовоспалительных препаратов и ингибиторов циклооксигеназы-2 в начале XXI века. Русский Медицинский журнал.  2003;11(7):375-8 [Nasonov EL. Primenenie nesteroidnyh protivovospalitelnyh preparatov I ingibitorov ciklooxigenasy-2 v nachale XXI veka. Russkii Meditsinskii zhurnal. 2003;11(7):375-8 (In Russ.)].  
11. Чичасова Н.В., Имаметдинова Г.Р., Иголкина Е.В., Насонов Е.Л. Найз в лечении хронических заболеваний суставов. Русский Медицинский журнал.  2012;(17) [Chichasova NV, Imametdinova GR, Igolkina EV, Nasonov EL. Naiz v lechenii hronicheskih zabolevanii sustavov. Russkii Meditsinskii zhurnal. 2012;(17) (In Russ.)].  https://medi.ru/info/11713/
12. Patompong Ungprasert, Wonngarm Kittanamongkolchai, Chrystal Price,  Supawat Ratanapo, Napat Leeaphorn, Daych Chongnarungsin, Wisit Cheungpasitporn. What Is The “Safest” Non-Steroidal Anti-Inflammatory Drugs? Am Medical J. 2012;3(2):115-23. doi: 10.3844/ amjsp.2012.115
13. Каратеев А.Е., Новикова Д.С., Насонов Е.Л. Новые данные, касающиеся безопасности нестероидных противовоспалительных препаратов: представление о «класс-специфическом» высоком кардиоваскулярном риске селективных ингибиторов циклооксигеназы-2 устарело. Научно-практическая ревматология. 2017;55(2):218-23. [Karateev AE, Novikova DS, Nasonov EL. New data on the safety of nonsteroidal anti-inflamatory drugs: the concept of the high class-specific cardiovascular risk of selective cyclooxygenase-2 inhibitors is outdated. Rheumatology Science and Practice. 2017;55(2):218-23 (In Russ.)]. doi: 10.14412/1995-4484-2017-218-223
14. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Archive Internal Medicine. 2009;169(2):141-9. doi: 10.1001/archinternmed.2008.525 
15. Martín Arias LH, Martín González A, Sanz Fadrique R, Vazquez ES. Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies. J Clin Pharmacol. 2019;59(1):55-73. doi: 10.1002/jcph.1302 
16. Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium.Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. British Medical J. 2016;354(28):i4857. doi: 10.1136/bmj.i4857
17. Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, et al. PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New England J Medicine. 2016;375(26):2519-29. doi: 10.1056/NEJMoa1611593  
18. Slomski A. Celecoxib Similar to 2 NSAIDs for Cardiovascular Safety. J Amer Medical Association. 2016;316(24):2589. doi: 10.1001/ jama.2016.19355
19. Ruschitzka F, Borer JS, Krum H, Flammer AJ, Yeomans ND, Libby P, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017;38(44):3282-92. doi: 10.1093/eurheartj/ehx508
20. White WB, Kloner RA, Angiolillo DJ, Davidson MH. Cardiorenal Safety of OTC Analgesics. J Cardiovasc Pharm Ther. 2018;23(2):103-18. doi: 10.1177/1074248417751070
21. Reed GW, Riaz H, Wang Q, Wolski K, Wisniewski L, Menon V, et al. Comparison of the safety of celecoxib, ibuprofen, andnaproxen in patients without established cardiovascular diseases. J Amer College of Cardiol. 2019;73(9)(suppl 1). doi: 10.1016/S0735-1097(19)30637-0 
22. Балабанова Р.М. Влияние селективных ингибиторов ЦОГ2 на сердечно-сосудистую систему при ревматических заболеваниях. Современная ревматология. 2010;4(2):88-93 [Balabanova RM. Cardiovascular effects of selective COX-2 inhibitorsin rheumatic diseases. Modern Rheumatol J. 2010;4(2):88-93 (In Russ.)]. doi: 10.14412/1996-7012-2010-609
23. Наумов А.В., Ткачева О.Н., Ховасова Н.О. К вопросу безопасности нестероидных противовоспалительных препаратов у пациентов с сердечно-сосудистым риском. Терапевтический архив. 2019;91(1):108-13 [Naumov AV, Tkacheva ON, Khovasova NO. Safety of nonsteroidal anti-inflammatory drugs in patients with cardiovascular risk. Therapeutic Archive. 2019;91(1):108-13 (In Russ.)]. doi: 10.26442/ 00403660.2019.01.000039
24. Лыгина Е.В. Эффективность и безопасность применения нимулида у больных остеоартрозом в сочетании с гипертонической болезнью. Российский медико-биологический вестник имени академика И.П. Павлова. 2006;(1):44-50 [Ligina EV. The effectiveness and safety of the use of nimulidus for people who have osteoarthritis with hypertonia. Rossiiskii medico-biologicheskii vestnik imini akademika IP Pavlova. 2006;(1):44-50 (In Russ.)].
25. Ejaz P, Bhojani K, Joshi VR.  NSAIDs and Kidney. JAPI. 2004;52: 632-40. www.japi.org
26. Dixit M,  Doan T,  Kirschner R,   Dixit N. Significant Acute Kidney Injury Due to Non-steroidal Anti-inflammatory Drugs: Inpatient Setting. Pharmaceuticals (Basel). 2010;3(4):1279-85. doi: 10.3390/ph3041279
27. Park KE, Qin Y, Bavry AA. Nonsteroidal anti-inflammatory drugs and their effects in the elderly. Aging Health. 2012;8(2):167-77. 
28. Leo RJ. Safe Analgesic Use in Patients with Renal Dysfunction. General guidelines for appropriate use of analgesics and co-analgesic adjuvants in pain patients with co-existing renal insufficiency. Practical Pain Management. 2014;8(5). https://www.practicalpainmanagement.com/treatments/pharmacologi cal/safe-analgesic-use-patients-renal-dysfunction?page=0,3
29. Chih-Cheng Hsu, Hongjian Wang, Yueh-Han Hsu, Shao-Yuan Chuang, Ya-Wen Huang, Yu-Kang Chang, et al. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension. Nationwide Longitudinal Cohort Study. Hypertension. 2015;66:524-33.  doi:/10.1161/HYPERTENSIONAHA.114.05105
30. Воронина H.B., Гельмутдинов Д.Д., Маркина О.И. Влияние нестероидных противовоспалительных препаратов – ингибиторов и не ингибиторов ЦОГ на состояние почек у больных оксалатной нефропатией, коморбидных по остеоартрозу. Дальневосточный медицинский журнал. 2016;1:14-9 [Voronina NV, Gelmutdinov DD, Markina OI. Iifluence of non-steroid anti-inflammatory drugs COX inhibitors and non-COX inhibitors on the condition of kidneys of patients suffering from oxalate nephropathy associated with osteoarthrosis. Dal’nevostochnyi meditsinskii zhurnal. 2016;1:14-9 (In Russ.)].
31. Nelson DA, Marks ES, Deuster PA, O’Connor FG, Kurina LM. Association of Nonsteroidal Anti-inflammatory Drug Prescriptions With Kidney Disease Among Active Young and Middle-aged Adults. J Amer Medical Association Netw Open. 2019;2(2):e187896. Published online February 15. doi: 10.1001/jamanetworkopen.2018.7896
32. Lai KM, Chen TL, Chang CC, Chen HH, Lee YW. Association between NSAID use and mortality risk in patients with end-stage renal disease: a population-based cohort study. Clin Epidemiol. 2019;11:429-41. doi: 10.2147/CLEP.S204322
33. Tan JHY, Hsu AAL. Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link. Respiratori Medicine. 2016;118:1-3. doi: 10.1016/j.rmed.2016.07.004
34. Bendlin BB, Newman LM,  Ries ML,  Puglielli L,  Carlsson CM,  Sager MA, et al. NSAIDs may protect against age-related brain atrophy. Frontiers Aging Neuroscience. 03 September 2010.  doi: 10.3389/fnagi. 2010.00035
35. Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly (Part I). Drugs Aging. 1991;1(2):130-43. doi: 10.2165/ 00002512-199101020-00005
36. Stillman MT. Interaction and Selection of Therapeutic Agents in the Elderly: NSAIDs and the Ageing Kidney. Scand J Rheumatol. 1989;18(suppl 82):33-8. doi: 10.3109/03009748909101467
37. Маянская С.Д., Каменская Л.Ю. Проблемы безопасности применения НПВП у пожилых пациентов с остеоартрозом в амбулаторной практике врача–терапевта. Русский Медицинский журнал. 2007;(22):1656-9 [Mayanskaya SD, Kamenskaya LYu. Problemy bezopasnosti primeneniya NPVP u pozhilyh patsientov s osteoartrozom v ambulatornoy praktike vracha terapevta.  Russkii Meditsinskii zhurnal. 2007;(22):1656-9 (In Russ.)].
38. van Leen MWF,  van der Eijk IA, Schols JMG. Prevention of NSAID gastropathy in elderly patients. An observational study in general practice and nursing homes. Age and Ageing.  2007;36(4):414-8. doi: 10.1093/ageing/ afm049
39. Makris UE, Kohler MJ, Fraenkel L. Adverse Effects of Topical Nonsteroidal Antiinflammatory Drugs in Older Adults with Osteoarthritis: A Systematic Literature Review. J Rheumatol. 2010;37(6):1236-43. doi: 10.3 899/jrheum.090935 
40. Taylor Jr R, Lemtouni S, Weiss K, Pergolizzi Jr JV. Pain Management in the Elderly: An FDA Safe Use Initiative Expert Panel’s View on Preventable Harm Associated with NSAID Therapy. Current Gerontology and Geriatrics Research. Volume 2012; Article ID 196159, 9 pages. doi: 10.1155/2012/196159
41. Пахомова И.Г., Хорошинина Л.П. Особенности применения нестероидных противовоспалительных препаратов у пожилых. Журнал неврологии и психиатрии. 2016;11:169-73 [Pakhomova IG, Khoroshinina LP.   Specifics of the use of NSAIDs in senior age. Zhurnal nevrologii i psihiatrii, 2016;11:169-73 (In Russ.)]. doi: 10.17116/ jnevro2016116111169-173
42. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in the Elderly. Aging Diseases. 2018 Feb;9(1):143-50. Published online 2018 Feb 1. doi: 10.14336/AD.2017.0306
43. Danelich IM, Wright SS, Lose JM, Tefft BJ, Cicci JD, Reed BN.  Safety of Nonsteroidal Antiinflammatory Drugs in Patients with Cardiovascular Disease. Pharmacother. 2015;35(5):520-35. doi: 10.1002/phar.1584
44. Milder TY,  Williams KM,  Ritchie JE,  Lipworth WL,  Day RO. Use of NSAIDs for osteoarthritis amongst older-aged primary care patients: engagement with information and perceptions of risk. Age and Ageing. 2011;40(2):254-9. doi:10.1093/ageing/afq160
45. EMA/696137/2012 Assessment report for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and cardiovascular risk. www.ema.europa.eu
46. Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, Hunt RH, and For the International NSAID Consensus Group. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Medicine. 2015;13:55. doi: 10.1186/s12916-015-0285-8
47. Roshi D, Toçi E, Burazeri G, Schröder-Bäck P, Malaj L, Brand H. Users’ Knowledge About Adverse Effects of Non-steroidal Anti-inflammatory Drugs in Tirana, Albania. Mater Sociomed. 2017;29(2):138-42. doi: 10.5455/msm.2017.29.138-42

________________________________________________

1. Shirinsky VS, Shirinsky IV. Comorbid diseases as an important problem of clinical medicine. Sibirskii meditsinskii zhurnal. 2014;29(1):7-12 (In Russ.) doi: 10.29001/2073-8552-2014-29-1-7-12
2. Karateev AE, Nasonov EL, Yakhno NN, Ivashkin VT, Chichasova NV, Alekseeva LI, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya revmatologiya. 2015;(1):4-23 (In Russ.) doi: 10.14412/1996-7012-2015-1-4-23 
3. Theodoridou A, Gika H, Diza E, Garyfallos A, Settas L. In vivo study of pro-inflammatory cytokine changes in serum and synovial fluid during treatment with celecoxib and etoricoxib and correlation with VAS pain change and synovial membrane penetration index in patients with inflammatory arthritis. Mediterranian J Rheumatol. 2017;28(1):43-50. doi: 10.31138/mjr.28.1.43
4. Metzner J, Popp L, Marian C, Schmidt R, Manderscheid C, Renne C, et al.  The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice. J Molecular Medicine (Berlin). 2007;85(6):623-33. doi: 10.1007/s00109-007-0162-9
5. Schmidt M, Lamberts M, Olsen A-MS, Fosbøll E, Niessner A, Tamargo J, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016;37(13):1015-23. doi:10.1093/eurheartj/ehv505
6. Varga Z, Sabzwari S, Vargova V. Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue Cureus. 2017 Apr; 9(4):e1144. Published online 2017 Apr 8. doi: 10.7759/cureus.1144 PMCID: PMC5422108
7. Morozova TE, Shmarova DG, Rykova SM. The choice of non-steroidal anti-inflammatory drugs in patients with rheumatologic profile with concomitant cardiovascular diseases. Lechashii vrach. 2016;(7):39-45 (In Russ.) 
8. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769-79. doi:10.1016/S0140-6736(13)60900-9
9. Zotova LA, Petrov VS. Nonsteroidal anti-inflammatory drugs in modern clinical practice: focus on safety. Nauka molodych. 2015;(1):25-30 (In Russ.) 
10. Nasonov EL. Primenenie nesteroidnyh protivovospalitelnyh preparatov I ingibitorov ciklooxigenasy-2 v nachale XXI veka. Russkii Meditsinskii zhurnal. 2003;11(7):375-8 (In Russ.)  
11. Chichasova NV, Imametdinova GR, Igolkina EV, Nasonov EL. Naiz v lechenii hronicheskih zabolevanii sustavov. Russkii Meditsinskii zhurnal. 2012;(17) (In Russ.)  https://medi.ru/info/11713/
12. Patompong Ungprasert, Wonngarm Kittanamongkolchai, Chrystal Price,  Supawat Ratanapo, Napat Leeaphorn, Daych Chongnarungsin, Wisit Cheungpasitporn. What Is The “Safest” Non-Steroidal Anti-Inflammatory Drugs? Am Medical J. 2012;3(2):115-23. doi: 10.3844/ amjsp.2012.115
13. Karateev AE, Novikova DS, Nasonov EL. New data on the safety of nonsteroidal anti-inflamatory drugs: the concept of the high class-specific cardiovascular risk of selective cyclooxygenase-2 inhibitors is outdated. Rheumatology Science and Practice. 2017;55(2):218-23 (In Russ.) doi: 10.14412/1995-4484-2017-218-223
14. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Archive Internal Medicine. 2009;169(2):141-9. doi: 10.1001/archinternmed.2008.525 
15. Martín Arias LH, Martín González A, Sanz Fadrique R, Vazquez ES. Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies. J Clin Pharmacol. 2019;59(1):55-73. doi: 10.1002/jcph.1302 
16. Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium.Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. British Medical J. 2016;354(28):i4857. doi: 10.1136/bmj.i4857
17. Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, et al. PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New England J Medicine. 2016;375(26):2519-29. doi: 10.1056/NEJMoa1611593  
18. Slomski A. Celecoxib Similar to 2 NSAIDs for Cardiovascular Safety. J Amer Medical Association. 2016;316(24):2589. doi: 10.1001/ jama.2016.19355
19. Ruschitzka F, Borer JS, Krum H, Flammer AJ, Yeomans ND, Libby P, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017;38(44):3282-92. doi: 10.1093/eurheartj/ehx508
20. White WB, Kloner RA, Angiolillo DJ, Davidson MH. Cardiorenal Safety of OTC Analgesics. J Cardiovasc Pharm Ther. 2018;23(2):103-18. doi: 10.1177/1074248417751070
21. Reed GW, Riaz H, Wang Q, Wolski K, Wisniewski L, Menon V, et al. Comparison of the safety of celecoxib, ibuprofen, andnaproxen in patients without established cardiovascular diseases. J Amer College of Cardiol. 2019;73(9)(suppl 1). doi: 10.1016/S0735-1097(19)30637-0 
22. Balabanova RM. Cardiovascular effects of selective COX-2 inhibitorsin rheumatic diseases. Modern Rheumatol J. 2010;4(2):88-93 (In Russ.) doi: 10.14412/1996-7012-2010-609
23. Naumov AV, Tkacheva ON, Khovasova NO. Safety of nonsteroidal anti-inflammatory drugs in patients with cardiovascular risk. Therapeutic Archive. 2019;91(1):108-13 (In Russ.) doi: 10.26442/ 00403660.2019.01.000039
24. Ligina EV. The effectiveness and safety of the use of nimulidus for people who have osteoarthritis with hypertonia. Rossiiskii medico-biologicheskii vestnik imini akademika IP Pavlova. 2006;(1):44-50 (In Russ.)
25. Ejaz P, Bhojani K, Joshi VR.  NSAIDs and Kidney. JAPI. 2004;52: 632-40. www.japi.org
26. Dixit M,  Doan T,  Kirschner R,   Dixit N. Significant Acute Kidney Injury Due to Non-steroidal Anti-inflammatory Drugs: Inpatient Setting. Pharmaceuticals (Basel). 2010;3(4):1279-85. doi: 10.3390/ph3041279
27. Park KE, Qin Y, Bavry AA. Nonsteroidal anti-inflammatory drugs and their effects in the elderly. Aging Health. 2012;8(2):167-77. 
28. Leo RJ. Safe Analgesic Use in Patients with Renal Dysfunction. General guidelines for appropriate use of analgesics and co-analgesic adjuvants in pain patients with co-existing renal insufficiency. Practical Pain Management. 2014;8(5). https://www.practicalpainmanagement.com/treatments/pharmacologi cal/safe-analgesic-use-patients-renal-dysfunction?page=0,3
29. Chih-Cheng Hsu, Hongjian Wang, Yueh-Han Hsu, Shao-Yuan Chuang, Ya-Wen Huang, Yu-Kang Chang, et al. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension. Nationwide Longitudinal Cohort Study. Hypertension. 2015;66:524-33.  doi:/10.1161/HYPERTENSIONAHA.114.05105
30. Voronina NV, Gelmutdinov DD, Markina OI. Iifluence of non-steroid anti-inflammatory drugs COX inhibitors and non-COX inhibitors on the condition of kidneys of patients suffering from oxalate nephropathy associated with osteoarthrosis. Dal’nevostochnyi meditsinskii zhurnal. 2016;1:14-9 (In Russ.)
31. Nelson DA, Marks ES, Deuster PA, O’Connor FG, Kurina LM. Association of Nonsteroidal Anti-inflammatory Drug Prescriptions With Kidney Disease Among Active Young and Middle-aged Adults. J Amer Medical Association Netw Open. 2019;2(2):e187896. Published online February 15. doi: 10.1001/jamanetworkopen.2018.7896
32. Lai KM, Chen TL, Chang CC, Chen HH, Lee YW. Association between NSAID use and mortality risk in patients with end-stage renal disease: a population-based cohort study. Clin Epidemiol. 2019;11:429-41. doi: 10.2147/CLEP.S204322
33. Tan JHY, Hsu AAL. Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link. Respiratori Medicine. 2016;118:1-3. doi: 10.1016/j.rmed.2016.07.004
34. Bendlin BB, Newman LM,  Ries ML,  Puglielli L,  Carlsson CM,  Sager MA, et al. NSAIDs may protect against age-related brain atrophy. Frontiers Aging Neuroscience. 03 September 2010.  doi: 10.3389/fnagi. 2010.00035
35. Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly (Part I). Drugs Aging. 1991;1(2):130-43. doi: 10.2165/ 00002512-199101020-00005
36. Stillman MT. Interaction and Selection of Therapeutic Agents in the Elderly: NSAIDs and the Ageing Kidney. Scand J Rheumatol. 1989;18(suppl 82):33-8. doi: 10.3109/03009748909101467
37. Mayanskaya SD, Kamenskaya LYu. Problemy bezopasnosti primeneniya NPVP u pozhilyh patsientov s osteoartrozom v ambulatornoy praktike vracha terapevta.  Russkii Meditsinskii zhurnal. 2007;(22):1656-9 (In Russ.)
38. van Leen MWF,  van der Eijk IA, Schols JMG. Prevention of NSAID gastropathy in elderly patients. An observational study in general practice and nursing homes. Age and Ageing.  2007;36(4):414-8. doi: 10.1093/ageing/ afm049
39. Makris UE, Kohler MJ, Fraenkel L. Adverse Effects of Topical Nonsteroidal Antiinflammatory Drugs in Older Adults with Osteoarthritis: A Systematic Literature Review. J Rheumatol. 2010;37(6):1236-43. doi: 10.3 899/jrheum.090935 
40. Taylor Jr R, Lemtouni S, Weiss K, Pergolizzi Jr JV. Pain Management in the Elderly: An FDA Safe Use Initiative Expert Panel’s View on Preventable Harm Associated with NSAID Therapy. Current Gerontology and Geriatrics Research. Volume 2012; Article ID 196159, 9 pages. doi: 10.1155/2012/196159
41. Pakhomova IG, Khoroshinina LP.   Specifics of the use of NSAIDs in senior age. Zhurnal nevrologii i psihiatrii, 2016;11:169-73 (In Russ.) doi: 10.17116/ jnevro2016116111169-173
42. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in the Elderly. Aging Diseases. 2018 Feb;9(1):143-50. Published online 2018 Feb 1. doi: 10.14336/AD.2017.0306
43. Danelich IM, Wright SS, Lose JM, Tefft BJ, Cicci JD, Reed BN.  Safety of Nonsteroidal Antiinflammatory Drugs in Patients with Cardiovascular Disease. Pharmacother. 2015;35(5):520-35. doi: 10.1002/phar.1584
44. Milder TY,  Williams KM,  Ritchie JE,  Lipworth WL,  Day RO. Use of NSAIDs for osteoarthritis amongst older-aged primary care patients: engagement with information and perceptions of risk. Age and Ageing. 2011;40(2):254-9. doi:10.1093/ageing/afq160
45. EMA/696137/2012 Assessment report for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and cardiovascular risk. www.ema.europa.eu
46. Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, Hunt RH, and For the International NSAID Consensus Group. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Medicine. 2015;13:55. doi: 10.1186/s12916-015-0285-8
47. Roshi D, Toçi E, Burazeri G, Schröder-Bäck P, Malaj L, Brand H. Users’ Knowledge About Adverse Effects of Non-steroidal Anti-inflammatory Drugs in Tirana, Albania. Mater Sociomed. 2017;29(2):138-42. doi: 10.5455/msm.2017.29.138-42

Н.С. Асфандиярова, Е.В. Филиппов

ФГБОУ ВО «Рязанский государственный медицинский университет им.  академика И.П. Павлова» Минздрава России, Рязань, Россия

________________________________________________

N.S. Asfandiyarova, E.V. Philippov

Ryazan State Medical University, Ryazan, Russia